Laekna Inc Stock price
Is Laekna Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Laekna Inc Stock Analysis
Analyst Opinions
10 Analysts have issued a Laekna Inc forecast:
Analyst Opinions
10 Analysts have issued a Laekna Inc forecast:
Don't miss a Thing! We will send you all news about Laekna Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Laekna, Inc. engages in the provision of clinical stage research and development of biopharmaceutical products. The company is headquartered in Ningbo, Zhejiang and currently employs 83 full-time employees. The company went IPO on 2023-06-29. The firm is still in the research and development stage. The firm's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The firm mainly conducts business in the Chinese, America, European, Korean, and other markets.
| Head office | Cayman Islands |
| CEO | Dr. Lu |
| Employees | 83 |
| Website | www.laekna.com |


